Modality
Small Molecule
MOA
HPK1i
Target
Aβ
Pathway
Ferroptosis
IPF
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
~Mar 2021
→ ~Jun 2022
Phase 2
Sep 2022
→ Jan 2029
Phase 2Current
NCT07112710
115 pts·IPF
2022-09→2025-02·Recruiting
NCT06714186
496 pts·IPF
2023-11→2029-01·Completed
611 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-02-201.1y agoPh3 Readout· IPF
2029-01-062.8y awayPh3 Readout· IPF
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P2/3
Recruit…
P2/3
Complet…
Catalysts
Ph3 Readout
2025-02-20 · 1.1y ago
IPF
Ph3 Readout
2029-01-06 · 2.8y away
IPF
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07112710 | Phase 2/3 | IPF | Recruiting | 115 | eGFR |
| NCT06714186 | Phase 2/3 | IPF | Completed | 496 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 |